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Summary In this study the kinetics and localisation of protoporphyrin IX (PpIX) fluorescence in skin and
skin tumours were examined after topically (20% for 4 h) or systemically (200 mg kg-', i.p.) administered 5-
aminolaevulinic acid (ALA). As a model we used hairless mice with skin lesions (actinic keratoses and squamous cell
carcinoma), which were induced by daily UVB irradiation. The epidermis of the skin surrounding the tumours (T)
was altered (AS); owing to the UVB irradiation, the epidermis was thicker and less elastic. Therefore, non-UVB-
irradiated mice were used to assess fluorescence of normal skin (NS). Light from a halogen lamp was used to excite
at 500 + 20 nm and fluorescence was detected through a filter that passes light of 670 + 50 nm. Maximal
fluorescence following i.p. ALA was observed 2 h post injection (p.i.) and was three times less than after topically
applied ALA. Furthermore, after i.p. ALA a lower T selectively (T/NS) could be obtained than after topically
applied ALA. Maximal fluorescence following topically applied ALA was achieved 6 h after the end of the 4 h
application time. At that interval fluorescence of T was twice as high as directly after the application period.
Furthermore, T selectivity (T/NS) after topical ALA at the interval of maximal fluorescence was higher than at the
interval directly after application. With fluorescence cryomicroscopy localisation of fluorescence in the skin at the
interval of maximal fluorescence was determined after both administration routes. For both cases fluorescence was
mainly located in T, epidermis and hair follicles. Fluorescence in subcutis could only be observed at 2 h post i.p.
ALA and at 6 h post topical ALA. No fluorescence could be observed in muscle. We conclude that, in this model
and with these ALA doses, a higher fluorescence intensity and selectivity (T/NS) was achieved after topically applied
ALA than after systemically administered ALA. These results make topically applied ALA more favourable for
ALA-PDT of superficial skin tumours in this model. In general these results imply that by optimising the time after
ALA application the efficacy and selectivity of topical ALA-PDT for skin tumours may be improved.
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A new approach in photodynamic therapy (PDT) to
photosensitise tumour tissue is the use of endogenously
produced photosensitisers. This can be achieved by admin-
istration of 5-aminolaevulinic acid (ALA), an agent which
utilizes the haem biosynthetic pathway, by bypassing the
feedback control of this pathway, to create diagnostic and
therapeutic levels of the sensitiser protoporphyrin IX (PpIX).
The activity of several enzymes involved in the haem
biosynthetic pathway varies in different tissue types. For
example, various malignant tissues have an increased
porphobilinogen deaminase activity, which converts ALA
into porphobilinogen, and a decreased ferrochelatase activity,
which converts PpIX into haem (van Hillegersberg et al., 1992).
This alteration in enzymatic activities may cause an increased
fluorescence in tumour tissue compared with normal tissue
after ALA administration (van der Veen et al., 1994; Bedwell et
al., 1992). Several normal tissues, especially those originating
from ecto- and endoderm may also become photosensitised
after exposure to ALA. This is in contrast to tissues from
mesodermal origin (Divaris et al., 1990; Loh et al., 1993).
In both human and animal studies ALA has been
administered by various routes. Topically applied ALA-
PDT has proven to be a successful treatment modality for
non-melanoma superficial malignant skin tumours (Kennedy
et al., 1990; Svanberg et al., 1994). Also, human studies have
been performed using orally applied ALA (Grant et al., 1993;
Regula et al., 1995) and topically applied ALA (Kriegmair et
al., 1994) for endoscopic PDT treatments as well as
photodetection of cancer. Sufficient tissue levels of PpIX for
diagnostic and treatment purposes can also be achieved by
administering ALA intravenously (i.v.) or intraperitoneally
(i.p.) as observed in animal studies by Tinuma et al. (1995)
and Peng et al. (1992).
Administering ALA by various routes may reveal a
dissimilarity in the bio-availability of ALA that may result in
different fluorescence dynamics and localisation of PpIX
fluorescence. To examine these differences in more detail, the
fluorescence kinetics after i.p. and topically administered ALA
ofsmall skin tumours was studied. Furthermore, localisation of
PpIX after both topical and i.p. ALA was examined using
fluorescence cyromicroscopy. As a model we used hairless mice
with small skin lesions (actinic keratoses and squamous cell
carcinomas), which were induced by UVB irradiation.
Materials and methods
Animal model
The animals used were inbred female hairless albino mice,
Skh hrl, 18 weeks old, obtained from the University of
Utrecht. These mice were irradiated daily with UVB light (1.5
kJ m-2) using a Westinghouse FS40TL12 lamp according to
a method described by de Gruijl et al. (1983). The lamps were
mounted above the cages so that mainly the dorsal skin of
the mice was exposed to the UVB light. The animals
developed multiple primary tumours in the exposed areas
after approximately 80 days. Small tumours (1-2 mm in
diameter), which were mainly squamous cell carcinoma,
actinic keratoses and seborrhoeic keratoses, were used in
the experiments. Non-UVB-irradiated animals were used to
assess normal skin fluorescence. This was necessary because
as a reaction to the daily UVB irradiation the skin was
altered and became thicker and less elastic.
ALA
5-Aminolaevulinic acid was obtained as hydrochloride in
98% pure powder form from Sigma (Bornem, Belgium). For
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the topical application ALA was dissolved in carboxymethyl-
cellulose 3% to yield a 20% solution. This non-fluorescing
transparent gel was used in order to follow the fluorescence
during the application period. The solvent was set at pH 5.5
by adding sodium hydroxide (2M), to avoid irritation of the
skin. Before ALA application the animals received a low dose
of diazepam (Centrafarm, Etten-leur, Holland) to avoid
anxiety and therefore movement of the solvent. The freshly
made solvent was placed on the entire dorsal skin and
covered with a gauze. A piece of transparent film dressing
(Mdlnlycke, Waremme, Belgium) was placed over the gauze
to achieve occlusion and to prevent evaporation and
movement of the solvent. The solvent was applied to the
skin for 4 h, after which it was carefully removed.
For systemic administration ALA was dissolved in
phosphate-buffered saline (PBS) after which the solution
was set at pH 6 using sodium hydroxide (2M) to prevent
necrosis at the injection site. The freshly made solution was
injected i.p. in a dose of 200 mg kg-.
Experimental set-up for in vivo experiments
Fluorescence kinetics after topically and i.p. administered
ALA was determined in six UVB- and six non-UVB-
irradiated mice per administration route. Fluorescence after
i.p. administered ALA was recorded every hour for 12 h. The
fluorescence after topical ALA was recorded every 2 h for
24 h. This long observation period after topical ALA made it
necessary to compose each 24 h series from two groups of
mice, each followed for 12 h. During the fluorescence
recordings the animals were anaesthetised with a combina-
tion of Ethrane/02/N20 and positioned on a temperature-
controlled stage under an intensified CCD camera. In each
UVB-irradiated mouse, after i.p. or topical ALA, three areas
each of 1 cm in diameter were recorded: two areas with
tumours and one that was macroscopically free of tumour. In
each non-UVB-irradiated mouse two randomly chosen areas
of 1 cm in diameter on the dorsal skin were recorded. Small
pieces of fluorescent plastic positioned in the recorded areas
were used for focusing on the skin and for corrections of
small variations in output of the excitation light. Light from
a halogen lamp and bandpass filter were used to excite
fluorescence at a wavelength of 500 + 20 nm with dose rate
of 0.2 mW cm-2. Through a dichroic mirror light was
projected on the skin and fluorescence was detected through a
filter that passes light of 670 + 50 nm. Fluorescence images
were recorded using a CCD camera with a two-stage image
intensifier and a 50 mm Leitz Photar macrolens. No
photodynamic damage caused by the excitation light could
be observed (total maximum excitation light dose of 0.04 J
cm-2). During the application period and between the
fluorescence recordings the animals were kept in the dark.
The recorded digitised images were analysed yielding
average grey-scale values per time interval of selected areas
of interest in tumours (T), UVB-irradiated skin (AS) and
non-UVB-irradiated skin (NS).
Fluorescence cyromicroscopy studies
For the fluorescence cryomicroscopy study the same adminis-
tration routes and ALA doses were applied as used with the
fluorescence kinetics studies. Fluorescence in T and in hair
follicles (HF), epidermis (EP), subcutis (SC) and muscle (M) of
AS and NS was examined at two intervals after ALA; directly
after 4 h application (t =4) and atmaximal fluorescence (t= 10;
6 h after the end of the application period). With systemic
ALA, fluorescence was only examined at intervals ofmaximum
fluorescence, which was 2 h (post injection) p.i. for T and AS
and 6 h p.i. for NS. Furthermore, unsensitised animals were
used to examine the autofluorescence ofT, AS and NS. Ateach
interval two animals were sacrificed, after which from each
animal two samples of 0.5 cm2, were excised and immediately
frozen in liquid nitrogen. From each sample, four transversal
sections of30gm thick were cut using a cryostat and placed on
a slide. The slides were kept in the dark and preserved in the
refrigerator.
The fluorescence set-up consisted of a CCD camera fitted
to a Leitz DM fluorescence microscope. Excitation light of
543 + 28 nm with an irradiance of 1 mW cm-2 was used and
fluorescence of a freshly made section was detected through a
615 nm high-pass filter. No photobleaching was observed
after the recordings (total energy was less than 0.01 J cm-2).
With phase contrast representative areas in four sections per
sample of T and HF, EP, SC and M of UVB- and non-UVB-
irradiated skin were identified and recorded. In the resulting
digitised images average fluorescence grey-scale values of
these structures were determined.
Results
Fluorescence kinetics studies
The fluorescence after topical ALA of T (n= 50), AS (n=6)
and NS (n= 12) observed in six animals per interval was
assessed every 2 h during 24 h (Figure la). The results after
i.p. administered ALA of T (n =50), AS (n=6) and NS
(n= 12), measured every hour over 12 h in six animals per
interval, are displayed in Figure lb. All values in these graphs
were corrected for background fluorescence using the
autofluorescence image, which had an average grey-scale
value of 29 for T, 27 for AS and 24 for NS. The grey-scale
values in Figure la and b are proportional to the fluorescence
with the same factor.
After topically applied ALA the rate of fluorescence
increase of T and AS was higher than NS. Furthermore,
maximum fluorescence of T and AS was attained at the same
interval, about 10 h after the start of the application. At that
interval the mean fluorescence intensity of tumours was 1.4
times higher than AS and four times higher than NS. After
10 h a rapid decrease in fluorescence was observed but even
ao a)
.i34
0
(a
>- 2(
o(
a
Time (h)
2( (1
5)
'0
CD
0
b
0 1 2 3 4 5 6 7 8 9 10 11 12
Time (h)
Figure 1 In vivo fluorescence kinetics, +s.e.m., expressed as
grey-scale values, of tumour (U), altered skin (El) and normal
skin (+) after topically (a) and systemically (b) administered
ALA. At each time interval the mean fluorescence (±s.e.m.) of
six animals is plotted, each corrected for their autofluorescence.
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_ Mat 24 h a certain amount of fluorescence could be detected.
Fluorescence of NS increased more slowly and the
fluorescence stayed at the same level between 6 and 24 h.
After i.p. administered ALA differences in the rate of
fluorescence increase between T and NS were observed as
shown in Figure lb. However, maximal fluorescence of both
T and AS was three times less than after topically applied
ALA. Maximal fluorescence intensity of NS after i.p. was
almost the same as after topically applied ALA. After i.p.
ALA maximal fluorescence in T and AS was achieved around
12 h whereas maximal fluorescence in NS was attained
around 6 h p.i. After interval of maximum fluorescence, a
decrease in the same rate as the fluorescence increase could be
observed. As a result, the fluorescence of T was only higher
than AS and NS until 4 h p.i., and after that time interval the
fluorescence of NS exceeded T and AS fluorescence. Twelve
hours p.i. fluorescence of T, AS and NS had almost returned
to autofluorescence level.
Fluorescence localisation studies
Mean fluorescence was determined in four sections per
sample of tumour (T), epidermal layer (EP), hair follicles
(HF), subcutis (SC) and muscle (M) of UVB- and non-UVB-
irradiated skin without ALA and after topical and systemic
ALA. Mean fluorescence per time interval was assessed in 16
sections per four samples obtained in two animals.
The fluorescence in UVB- and non-UVB-irradiated mice
examined directly (t=4) and 10 h after start of topical ALA
application is shown in Figure 2a and b. In unsensitised
UVB- and non-UVB-irradiated animals only a low auto-
fluorescence signal was observed in all structures. Directly
after ALA application fluorescence in UVB-irradiated skin
(Figure 2a) was mainly located in HF, EP and in T. Between
these structures similar fluorescence intensities were observed.
No fluorescence could be detected in SC and M. Fluorescence
at 10 h was also located in T, EP and HF and was twice as
high as 4 h. No fluorescence could be observed in M but a
low fluorescence level in SC was detected at 10 h. In non-
UVB-irradiated skin (Figure 2b) fluorescence could, be
detected at both 4 and 10 h in EP and HF but not in SC
and M. The increase in fluorescence in EP and HF at 10 h
was small and not significantly different from 4 h. Differences
in fluorescence intensities at 4 h between HF and EP of
UVB- and non-UVB-irradiated skin were not significantly
different. However, at 10 h the fluorescence in EP and HF of
UVB-irradiated skin was approximately twice as high as in
EP and HF of non-UVB-irradiated skin.
Fluorescence after i.p. administered ALA, shown in Figure
2c, was determined at 2 h p.i. for UVB- and 6 h p.i. for non-
UVB-irradiated mice. In UVB-irradiated skin fluorescence
was mainly located in T, HF and EP. A low level of
fluorescence could be detected in SC whereas no fluorescence
was observed in M. Fluorescence intensity of HF, EP and M
at 6 h p.i. in non-UVB-irradiated mice was similar to
fluorescence of UVB-irradiated mice at 2 h p.i., except in
SC of non-UVB-irradiated skin where no fluorescence could
be detected. The fluorescence intensities of T. EP, HF in
UVB-irradiated mice after i.p. ALA were similar to intensities
found in UVB-irradiated mice at the interval directly after
application (4 h).
Discussion
In this study the differences in kinetics and localisation of
PpIX fluorescence between topically and systemically
administered ALA of small skin tumours, induced by mice
by daily UVB-irradiation, were determined. Human skin
cancers, particularly basal cell and squamous cell carcinomas,
are also closely associated with chronic, repeated exposure of
the skin to solar UV radiation (Fears et al., 1976). De Gruijl
et al. (1983) reported that in this model the fraction of actinic
keratoses decreases with increasing diameter whereas the
PpIX fluorescence and localisation in skin tumours after topical and i.p. ALA U
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fraction of squamous cell carcinoma increases with increasing
diameter. This means roughly that tumours smaller than 2
mm mainly consist of actinic keratoses whereas tumours
between 2 and 4 mm in diameter mainly consist of squamous
cell carcinoma. In this study only small tumours of
approximately 2 mm (actinic keratoses and squamous cell
carcinoma) were included. Larger tumours revealed consider-
able variations in appearance and incidence of necrosis or
bleeding on top of the tumours.
In human skin a thickening of the epidermis is seen after
exposure to sunlight. This reaction is only temporary and the
thickness returns to normal values within weeks when the
skin is no longer exposed to sunlight. Also in mouse skin this
epidermal thickening due to UVB-irradiation was observed.
Sterenborg et al. (1986) found that this reaction is UVB dose
dependent. They also observed that the thickness of the
stratum corneum was roughly proportional to the thickness
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Figure 2 Results of fluorescence, cryomicroscopy, expressed as
grey-scale values (± s.e.m.), in tumour (T), epidermis (EP), hair
follicles (HF), subcutis (SC) and muscle (M) are displayed in (a),
(b) and (c). (a) The fluorescence before (t=0), directly after (t=4)
and 6 h after (t= 10) topically applied ALA of structures in UVB-
irradiated skin are displayed. (b) The fluorescence of structures in
non-UVB-irradiated skin after topical ALA, determined at similar
intervals as shown (a). (c) The fluorescence after i.p. administered
ALA, before and at 2 h p.i. in UVB-irradiated skin and at 6 h p.i.
in non-UVB-irradiated skin are displayed.
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of the whole epidermis. The UVB doses used in this
experiment were at the threshold for producing oedema. As
a reaction to the high daily doses of UVB light an acute
thickening of epidermis occurred that is no longer UVB dose
dependent (Sterenborg et al., 1986). This acute reaction is
maintained longer and is only partly reversible. This made it
necessary to use non-UVB-irradiated animals to examine the
fluorescence of normal skin.
Differences in fluorescence kinetics between UVB and non-
UVB irradiated mice
The variation in thickness of epidermis between non-UVB
and UVB-irradiated mice accounts to some extent for the
differences in fluorescence kinetics between T. AS and NS
observed after both topically and systemically administered
ALA. The thickness of the epidermis in the skin of non-
UVB-irradiated mice is 23 gm (s.e.m. + 1) whereas in UVB-
irradiated skin the epidermal thickness is 52 gum (s.e.m. + 5).
The thickness in UVB-irradiated skin of tumour with the
underlying epidermis is 404 gum (s.e.m. + 70). We observed
with fluorescence cryomicroscopy a significant amount PpIX
fluorescence in the epidermal layer. Therefore a higher
fluorescence increase and intensity in UVB-irradiated skin
than in non-UVB-irradiated skin can be expected with our
fluorescence set-up.
The importance of the thickness of the epidermal layer for
the fluorescence increase and intensity is confirmed by our
fluorescence cryomicroscopy study. With this method, which
excludes variations in epidermal thickness and elevated
tumours, no significant differences in fluorescence intensities
between T and AS fluorescence were observed. However,
with fluorescence cryomicroscopy a significant difference in
fluorescence intensity (factor 2) at 6 h after application
between T (and AS) and NS was observed. Therefore,
differences in kinetics between a slightly elevated T, a
thickened AS and NS can only partly be accounted for by
variations in thickness of the epidermal layer.
A factor that also may explain the higher rate of
fluorescence increase in T and AS compared with NS is an
altered activity of enzymes involved in the haem biosynthetic
pathway in T and AS. It is known that the activity of two
enzymes, porphobilinogen deaminase and ferrochelatase, can
be changed in malignant tissues (van Hillegersberg et al.,
1992). This may result in a steeper rate of fluorescence
increase in T and AS compared with NS after both topically
and systemically administered ALA. That a disparity in
enzymatic activity is an important factor in a different rate of
fluorescence increase was supported by a previous study with
a different animal model (van der Veen et al., 1994). In this
model the same differences in rate of fluorescence increase
between T and surrounding subcutaneous tissue were
observed after i.v. administered ALA. Furthermore, in both
T and subcutaneous tissue no enlargement in rate of
fluorescence increase occurred after doubling of the adminis-
tered ALA dose. This observation confirmed that the higher
rate of fluorescence increase in T and AS could represent a
higher capacity for conversion of ALA to porphyrin or a
lower capacity of conversion of PpIX to haem or a
combination of both. It also excludes that differences in
rate of fluorescence increase after systemic ALA were
determined by a disparity in ALA uptake, vascularisation
or quality of blood vessel wall between T and NS. Otherwise,
an enhancement in rate of fluorescence increase would be
expected after a 2-fold ALA dose. Variations in ALA uptake
and vascularisation may however account for differences in
maximal fluorescence intensities after systemically adminis-
tered ALA.
Differences in fluorescence kinetics between topically and i.p.
administered ALA
Between i.p. and topically administered ALA clear differences
in fluorescence kinetics and T, AS and NS were observed.
There was a large difference in interval of reaching maximal
fluorescence. The difference may be the result of a
dissimilarity in the bio-availability of ALA between both
administration routes.
With systemically administered ALA maximal fluorescence
in T and AS occurred 2 h p.i. whereas maximal NS
fluorescence was reached 6 h p.i. This short interval of
fluorescence increase in T and AS may be caused by a
combination of a limited retention of ALA in the circulation
and an increased PpIX synthesis. After systemic ALA
administration a substantial fraction of ALA will be
accumulated by the liver. ALA is also rapidly cleared from
the circulation, resulting in a strong reduction of ALA in the
course of time. Therefore, it is likely that maximal ALA
accumulation takes place directly p.i. and that ALA, or an
intermediate of the haem synthesis, is retained in the cells. As
a result, ALA or intermediates will be depleted faster in T and
AS than in NS owing to the increased PpIX synthesis in T and
AS. This may explain the disparity in time required to reach
maximal fluorescence between T and NS, a phenomenon also
observed by Peng et al. (1992) and van der Veen et al. (1994).
This difference between tissues in interval to reaching
maximal fluorescence may be an important element in
determining the time interval p.i. for PDT treatment. For
example if treatment in this model were performed at 6 h p.i.,
an interval when fluorescence in NS is three times higher than
in T, no T damage but severe NS damage could be expected.
That relatively small variations in time interval p.i. for PDT
treatments may result in large variations in damage effect on
T and normal tissues has been illustrated by several studies.
Peng et al. (1992) observed maximal fluorescence in
mammary T at 1 h p.i. whereas maximal skin fluorescence
was observed 3 h p.i. They observed a delay of T growth
treating at 1 h p.i. (maximal fluorescence) but no delay of
growth treating at 5 h p.i. Also, Orth et al. (1994) examined
the fluorescence after systemically administered ALA in
mouse skin and in a subcutaneously transplanted colonic
tumour. At 3 h p.i. they found a higher fluorescence intensity
in skin than in T and no T damage after a single treatment at
3 h p.i. could be obtained. Furthermore, van der Veen et al.
(1994) found no direct correlation between fluorescence
intensity and the amount of vascular damage to tumour
and normal tissue after systemic ALA administration.
These results emphasise the importance of further studies
on the relationship between fluorescence kinetics and
optimum interval of PDT treatment of tumours and host
tissues before systemic ALA-PDT can be a successful and
reliable treatment modality for human studies. Furthermore,
it also seems necessary to investigate whether the bio-
availability of ALA can be improved by, for example, using
liposomes (Fukuda et al., 1989) as a carrier system. A
successful option for increasing the retention of ALA in the
circulation is by administering fractionated ALA doses.
Regula et al. (1995) were able to produce plateau levels of
ALA in patients by six fractionated ALA doses given orally
at hourly intervals.
In contrast to systemically administered ALA, maximal
fluorescence in T and AS after topical ALA was reached 6 h
after the end of the application period. Malik et al. (1995)
observed an increase in fluorescence intensity of normal
mouse skin up to 2-4 h after the end of 2 h topically applied
ALA. It may be possible that during the 4 h application, on
the skin of hairless mice, a large depot of ALA is formed in
the horny layer or in other parts of the skin. This ALA can
be metabolised over a long period oftime, which may explain
this long interval of fluorescence increase in T and AS.
Fluorescence in NS increased only up to 4 h after
application, after which the fluorescence stayed at the same
level. As a result maximal fluorescence intensity in T was four
times higher than in NS. This is in contrast with systemically
administered ALA in which fluorescence of T and 2 h p.i.
was only 1.8 times higher than NS fluorescence. The
increased selectivity of T and AS over NS after topically
applied ALA may be the consequence of an altered skinPpIX fluorescence and localisation in skin tumours after topical and i.p. ALA
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barrier of T and AS. The abnormal layer of keratin that is
produced by some skin tumours such as squamous cell
carcinoma is rapidly penetrated by ALA. Also, skin that
shows evidence of chronic sunburn damage and actinic
keratoses usually shows an increased penetration of ALA.
This was illustrated by Goff et al. (1992) who induced a
disrupted stratum corneum by tape stripping the skin of
guinea pigs and found an increased damage effect after
topical ALA-PDT compared with ALA-PDT on skin with an
intact stratum corneum. Because ofthe altered skin barrier of
T and AS an increased ALA depot in the skin may be formed
during the application period, which may result in an increase
in fluorescence over a long period of time. In NS less ALA
can penetrate the skin during the application period because
of an intact skin barrier. This may then result in an increased
selectivity of T and AS compared with NS until the interval
of maximal fluorescence.
At 10 h after the start ofapplication fluorescenceintensity in
T and AS was at least 1.5 times higher than directly after the
application period. Furthermore, the fluorescence ratio of T
compared with NS between 4 and 10 h had increased from 3.3
to 4.3. This increase in fluorescence intensity and selectivity
implies that treatment directly after 4-6 hALA application, as
commonly applied in human studies (Cairnduff et al., 1994;
Wolf et al., 1993; Svanberg et al., 1994), may not be optimal.
Instead, 4-6 h of ALA application and postponing illumina-
tion for another 4-6 h may result in improved tumour
response and improved therapeutic ratio.
Another option for increasing the fluorescence intensities
after topical ALA is prolonging the ALA application period.
Szeimies et al. (1994) observed an increase in fluorescence
intensity in human basal cell carcinoma by applying ALA for
12 h instead of a 4 h application period. However, with this
prolonged application interval they also observed an increase
in fluorescence in surrounding normal tissue. Also in our
clinic we have used a prolonged ALA application (16-19 h)
for treating skin malignancies with ALA-PDT. With this
prolonged application more damage effect after ALA-PDT is
observed but in contrast with a 4 h application period hardly
any difference in fluorescence between T and surrounding
skin can be observed. Nevertheless, the therapeutic ratio and
cosmetic effect are not adversely affected. It may be possible
that, owing to a prolonged ALA application and therefore
prolonged occlusion, the difference in ALA penetration
between T and surrounding skin diminishes. Considering
the results obtained with the experiments in hairless mice it
may be more favourable to apply ALA for a limited time and
illuminate the applied area at a later interval.
The influence of the interval of ALA application on
selectivity and fluorescence intensities will be investigated in
further studies. Also studies will be performed to examine the
correlation between fluorescence intensities and therapeutic
effects by treating at different intervals after topically applied
ALA.
Fluorescence localisation study
The results obtained with the fluorescence cryomicroscopy
study showed no important variations in localisation of PpIX
fluorescence in the skin between topically and systemically
administered ALA. Fluorescence after both administration
routes in NS and AS was mainly localised in the epidermal
layer and in the hair follicles. No fluorescence could be
detected in the muscle layer. In AS a small increase in
fluorescence could be observed in the submucosa at 2 h post
i.p. and at 6 h after topical ALA application. For topical
ALA this could imply that in the course of time ALA slowly
penetrates the epidermal layer into the dermal layer.
With the fluorescence kinetics study we even observed
some fluorescence at 20 h after ALA application. This
fluorescence was spotty and inhomogeneous and was mainly
observed in the tumours that were macroscopically rough on
the surface. In a pilot fluorescence cryomicroscopy study it
became clear that this fluorescence was located in necrosis of
tumours and some areas of the stratum corneum of the
tumour. This may be caused by porphyrins excreted from
cells and diffused to the necrotic parts in the tumour.
Fluorescence in stratum corneum in humans was also
observed by Szeimies et al. (1994) after a 12 h application
period. They suggested that this fluorescence could also be
synthesised by bacteria.
Conclusions
In the hairless mouse model we observed differences in
fluorescence kinetics between topically and systemically
administered ALA. The most obvious differences between
both administration routes were the maximal fluorescence
intensity and the interval to reaching maximal fluorescence in
T and AS. Because of the disparity in bio-availability
maximal fluorescence after systemic ALA in T was reached
early (2 h p.i.) but was three times lower than maximal
fluorescence after topical ALA, which occurred at 10 h after
the start of ALA application. Furthermore, a higher
selectivity of T compared with NS could be observed after
topically applied ALA. These differences make topically
applied ALA probably more favourable for a successful
ALA-PDT in this model than systemic ALA.
In general it can be concluded that by optimising the time
of ALA application or interval after ALA application the
efficacy and selectivity of topical ALA-PDT for skin tumours
may be improved.
Abbreviations
ALA, 5-aminolaevulinic acid; PpIX, protoporphyrin IX; T,
tumour; AS, UVB-irradiated skin; NS, non-UVB-irradiated skin;
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